Danish Vaccine Batch Study: Adverse Reaction Patterns and EMA Oversight

The, um, as you can see in front of you on this

screen, uh, is the

result, the main result of our study.

Uh, it shows from the, uh, official Danish

data that we queried f-uh, for the study.

It shows each batch and how many, um, how many

adverse reactions

were present in each batch.

You can see that along the Y-axis, the vertical axis,

and along the, uh, horizontal axis, you can see

how big were the batches. As you can see from the graph,

um,

some of these batches are very small, some of them are very

big.

And

in this case, if we, uh, assume that we would see a

normal vaccine, a really good vaccine, something that was very consistently

produced, we would see a near perfect line.

One near perfect line. If we, on the other hand, produced

a really horrible vaccine, the worst one we could possibly conceive,

we

would see no line. We would see just scattered dots.

Um, in this case, we see three.

Not one, but we see three lines, and they are actually near

perfect.

The problem with this is that it's obviously, uh, it, it's

something that is completely outside the category of what we should expect

to see in adverse, adverse data. That's the main finding

of this study. But something that is also very troubling is

this shows a system. It shows a structure

in the data.

Adverse reactions, error, uh, errors in production

are, by nature, they're random, but this shows structure.

We do not know yet why, uh, but we're obviously

researching this, this issue. So there are three different

types of batches, and every batch gives another, uh, uh,

risk. And, uh, the, the,

the blue one gives the highest mortality risk.

Um, and nobody knew upfront which batch you would

get. Nobody knew that there was this difference

between these batches. Nobody knew.

But the EMA gets samples of every batch, and they can

test it, and they can see whether or not they, they are identical.

And that's their job, because their job is to protect us

from, uh, mistakes made by pharmaceutical industry.

Uh, and that is also something that in a second letter to the EMA, we

are going to

address. Be sure of that. Uh, as are the things as

contamination, uh, by DNA of bacteria in the,

in the vaccines, as, uh, are the things that, uh,

Joachim mentioned about are there two databases with

adverse, uh, events. Um, um, how come that the,

uh, EMA never warned us